Literature DB >> 30113631

ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up.

F Honecker1, J Aparicio2, D Berney3, J Beyer4, C Bokemeyer5, R Cathomas6, N Clarke7, G Cohn-Cedermark8, G Daugaard9, K-P Dieckmann10, K Fizazi11, S Fosså12, J R Germa-Lluch13, P Giannatempo14, J A Gietema15, S Gillessen16, H S Haugnes17, A Heidenreich18, K Hemminki19, R Huddart20, M A S Jewett21, F Joly22, J Lauritsen9, A Lorch23, A Necchi14, N Nicolai24, C Oing5, J Oldenburg25, D Ondruš26, A Papachristofilou27, T Powles28, A Sohaib29, O Ståhl30, T Tandstad31, G Toner32, A Horwich33.   

Abstract

The European Society for Medical Oncology (ESMO) consensus conference on testicular cancer was held on 3-5 November 2016 in Paris, France. The conference included a multidisciplinary panel of 36 leading experts in the diagnosis and treatment of testicular cancer (34 panel members attended the conference; an additional two panel members [CB and K-PD] participated in all preparatory work and subsequent manuscript development). The aim of the conference was to develop detailed recommendations on topics relating to testicular cancer that are not covered in detail in the current ESMO Clinical Practice Guidelines (CPGs) and where the available level of evidence is insufficient. The main topics identified for discussion related to: (1) diagnostic work-up and patient assessment; (2) stage I disease; (3) stage II-III disease; (4) post-chemotherapy surgery, salvage chemotherapy, salvage and desperation surgery and special topics; and (5) survivorship and follow-up schemes. The experts addressed questions relating to one of the five topics within five working groups. Relevant scientific literature was reviewed in advance. Recommendations were developed by the working groups and then presented to the entire panel. A consensus vote was obtained following whole-panel discussions, and the consensus recommendations were then further developed in post-meeting discussions in written form. This manuscript presents the results of the expert panel discussions, including the consensus recommendations and a summary of evidence supporting each recommendation. All participants approved the final manuscript.

Entities:  

Mesh:

Year:  2018        PMID: 30113631     DOI: 10.1093/annonc/mdy217

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  51 in total

1.  Metastatic Mediastinal Germ-Cell Tumor and Concurrent COVID-19: When Chemotherapy Is Not Deferrable.

Authors:  Paolo Pedrazzoli; David Rondonotti; Carlo Cattrini; Simona Secondino; Paolo Ravanini; Antonio Piralla; Pier Paolo Sainaghi; Diego Brustia; Cristina Bozzola; Marisa Gariglio; Christian Cossandi; Giovanni Rosti; Alessandra Gennari
Journal:  Oncologist       Date:  2020-12-20

2.  Prognostic factors for relapse in stage I testicular seminoma: tumor size and rete testis invasion revisited.

Authors:  J Aparicio
Journal:  Clin Transl Oncol       Date:  2018-05-09       Impact factor: 3.405

3.  Early experience with chemotherapy intensification for poor-prognosis metastatic germ cell cancer and unfavorable tumor marker decline.

Authors:  Anupam Batra; Scott Ernst; Kylea Potvin; Ricardo Fernandes; Nicholas Power; James Vanhie; Eric Winquist
Journal:  Can Urol Assoc J       Date:  2019-07-23       Impact factor: 1.862

Review 4.  The role of diagnostic imaging in the primary testicular cancer: initial staging, response assessment and surveillance.

Authors:  Kerry L Thomas; Daniel Jeong; Jaime Montilla-Soler; Sebastian Feuerlein
Journal:  Transl Androl Urol       Date:  2020-01

Review 5.  Clinical dilemmas in local and regional testis cancer.

Authors:  Gregory J Nason; Ricardo A Rendon; Lori Wood; Robert A Huddart; Peter Albers; Lawrence H Einhorn; Craig R Nichols; Christian Kollmannsberger; Lynn Anson-Cartwright; Padraig Warde; Michael A S Jewett; Peter Chung; Philippe L Bedard; Aaron R Hansen; Robert J Hamilton
Journal:  Can Urol Assoc J       Date:  2021-01       Impact factor: 1.862

Review 6.  Management of Residual Mass in Germ Cell Tumors After Chemotherapy.

Authors:  Costantine Albany; Kenneth Kesler; Clint Cary
Journal:  Curr Oncol Rep       Date:  2019-01-21       Impact factor: 5.075

Review 7.  Human germ cell tumours from a developmental perspective.

Authors:  J Wolter Oosterhuis; Leendert H J Looijenga
Journal:  Nat Rev Cancer       Date:  2019-08-14       Impact factor: 60.716

Review 8.  The Diagnostic Accuracy of miR-371a-3p for Testicular Germ Cell Tumors: A Systematic Review and Meta-Analysis.

Authors:  Qiangzhao Liu; Qiong Lian; Haidi Lv; Xiaofeng Zhang; Fenghai Zhou
Journal:  Mol Diagn Ther       Date:  2021-04-22       Impact factor: 4.074

9.  The combination of microRNA-371a-3p and 375-5p can distinguish viable germ cell tumor and teratoma from necrosis in postchemotherapy retroperitoneal lymph node dissection specimens.

Authors:  Lara Kremer; Melanie von Brandenstein; Maike Wittersheim; Barbara Koeditz; Pia Paffenholz; Martin Hellmich; David Pfister; Axel Heidenreich; Tim Nestler
Journal:  Transl Androl Urol       Date:  2021-04

Review 10.  Late adverse effects and quality of life in survivors of testicular germ cell tumour.

Authors:  Michal Chovanec; Jakob Lauritsen; Mikkel Bandak; Christoph Oing; Gry Gundgaard Kier; Michael Kreiberg; Josephine Rosenvilde; Thomas Wagner; Carsten Bokemeyer; Gedske Daugaard
Journal:  Nat Rev Urol       Date:  2021-03-08       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.